Development of Robust and Innovative Vaccine Effectiveness
DRIVE logo


Start Date
End Date
IMI2 - Call 9
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
8 999 813
EFPIA in kind
1 000 125
Total Cost
9 999 938


Influenza is a major public health issue; it is thought to infect some 60 million of the EU’s 500 million inhabitants every year. Vaccines have a major role to play in preventing the spread of the infectious disease, every year, the World Health Organization (WHO) studies the strains of flu in circulation worldwide and recommends adaptations to flu vaccines accordingly. The challenge for the entire vaccine research and healthcare community is to evaluate the effectiveness of these annual vaccines. Current efforts in this area are simply not extensive enough to assess in detail the benefits of vaccination for different groups and to guide public health measures during a flu season. One element hampering efforts to carry out more extensive vaccine effectiveness is the ability of the different stakeholders involved to work in collaboration.

The goal of the DRIVE project is to set up a platform, bringing together all stakeholders, to study brand-specific flu vaccine effectiveness in the EU over a five-year period. At the heart of the platform will be a governance framework that allows transparent and efficient collaboration between public and private stakeholders. To guarantee the scientific independence of the studies, the roles of all participants, including vaccine manufacturers, will be clearly defined and traceable. An Independent Scientific Committee will further minimise the risk of conflicts of interest in the design of the studies and the interpretation of their results.

Achievements & News

Join the DRIVE flu vaccine effectiveness network
May 2018

The DRIVE project has launched a Call for tenders for organisations to join the project’s network on influenza vaccine effectiveness (IVE). DRIVE is working to create a European platform for studying brand-specific IVE and develop a governance model for scientifically robust, independent and transparent studies in a public-private partnership. ###The DRIVE partners include public health institutes, universities, research organisations, small and medium-sized enterprises and large pharmaceutical companies. The goal of the project’s Call for tenders, which is open to any European organisation, institution or network, is to support the sharing of existing IVE data and to establish new IVE studies. Successful applicants will become DRIVE Research Collaborators and will receive compensation from the project for data and analyses contributed and for participating in relevant project meetings.

Participants Show participants on map

EFPIA companies
  • Abbott Biologicals BV, Weesp, Netherlands
  • GlaxoSmithKline Biologicals, Rixensart, Belgium
  • Sanofi Pasteur SA, Lyon, France
  • Seqirus Uk Limited, Maidenhead, United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Association Internationale De Standardisation Biologique Pour L'Europe (Iabs-Eu), Lyon, France
  • Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana, Valencia, Spain
  • Institut De Recherche Pour Le Developpement, Marseille, France
  • Istituto Superiore Di Sanita, Roma, Italy
  • Terveyden Ja Hyvinvoinnin Laitos, Helsinki, Finland
  • Universita Degli Studi Di Firenze, Florence, Italy
  • Universite Lyon 1 Claude Bernard, Villeurbanne, France
  • University Of Surrey, Guildford, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • P95 CVBA, Leuven, Belgium
  • Synapse Research Management Partners SL, Barcelona, Spain
Patient organisations
  • Confederation Of Meningitis Organisations LTD, Bristol, United Kingdom


Project coordinator
Project leader
Cedric MAHE